Mechanism of action
Join Us in Advancing the Next Generation of IgM Therapeutics
Our proprietary IgM-based drug delivery technology is being developed to address significant challenges in targeted therapeutics and unlock new opportunities across multiple disease areas.
We are currently raising pre-seed capital to achieve key milestones, including preclinical proof-of-concept studies, expansion of our intellectual property portfolio, and generation of value-driving data that will support future financing and partnering opportunities.
We are seeking investors and strategic partners who recognize the potential of innovative biologics and share our commitment to transforming therapeutic delivery.
